Skip to Content
Merck

SML0117

Fosphenytoin disodium salt hydrate

≥98% (HPLC)

Synonym(s):

5,5-Diphenyl-3-[(phosphonooxy)methyl]-2,4-imidazolidinedione disodium salt hydrate

Sign In to View Organizational & Contract Pricing.

Select a Size

All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C16H13N2Na2O6P · xH2O
CAS Number:
92134-98-0
Molecular Weight:
406.24 (anhydrous basis)
NACRES:
NA.77
PubChem Substance ID:
329825169
UNSPSC Code:
12352200
MDL number:
MFCD20527322

Product Name

Fosphenytoin disodium salt hydrate, ≥98% (HPLC)

InChI

1S/C16H15N2O6P.2Na.H2O/c19-14-16(12-7-3-1-4-8-12,13-9-5-2-6-10-13)17-15(20)18(14)11-24-25(21,22)23;;;/h1-10H,11H2,(H,17,20)(H2,21,22,23);;;1H2/q;2*+1;/p-2

SMILES string

O.[Na+].[Na+].[O-]P([O-])(=O)OCN1C(=O)NC(C1=O)(c2ccccc2)c3ccccc3

InChI key

WPAVXKKGWCHUAK-UHFFFAOYSA-L

assay

≥98% (HPLC)

form

powder

color

white to tan

solubility

H2O: ≥15 mg/mL

storage temp.

2-8°C

Quality Level

100

Biochem/physiol Actions

anticonvulsant
Fosphenytoin is a water soluble phenytoin prodrug.

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Carc. 1B - Repr. 1B

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
081M4625V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Tomoyuki Akiyama et al.
Brain and nerve = Shinkei kenkyu no shinpo, 62(5), 519-526 (2010-05-11)
In this review study, second-generation antiepileptic drugs (AEDs) (levetiracetam, gabapentin, topiramate, lamotrigine, zonisamide, oxcarbazepine, vigabatrin, pregabalin, rufinamide, tiagabine, lacosamide, and felbamate) and injectable AEDs (levetiracetam, lacosamide, fosphenytoin, lorazepam, and valproic acid) available in North America were compared with those available
Kai Eriksson et al.
Expert opinion on drug metabolism & toxicology, 5(6), 695-701 (2009-05-29)
Fosphenytoin, phosphate ester pro-drug of phenytoin, was developed to overcome complications associated with parenteral phenytoin administration in treatment of acute symptomatic seizures, short-term prophylaxis and treatment of repetitive or prolonged seizures and status epilepticus. To evaluate the current position of
Minimum requirements for approval of a drug in status epilepticus.
Michel Baulac et al.
Epilepsia, 50 Suppl 12, 77-78 (2009-11-28)
Sandeep Soni et al.
Pediatric blood & cancer, 59(4), 762-764 (2012-03-02)
Anti-seizure prophylaxis is routinely utilized during busulfan administration for HSCT. We evaluated the feasibility and efficacy of levetiracetam in children undergoing HSCT. A total of 28 children and young adults received levetiracetam during HSCT and the outcomes and costs were
Mounzer Y Kassab et al.
Epilepsy research, 87(2-3), 268-271 (2009-10-27)
To study the incidence and extent of the occasionally noted hypotension after intravenous (IV) infusions of fosphenytoin (FOS) and levetiracetam (LEV) in patients presenting with acute cerebral symptoms. Retrospective data collection of consecutive patients with acute cerebral symptoms who received
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service